Sealed Air Corp. announced financial results for fourth quarter and full year 2013.
In a release on February 6, the Company noted:
Commenting on these results, Jerome A. Peribere, President and Chief Executive Officer, said, "2013 was a solid year for Sealed Air - we generated $509 million of Free Cash Flow, increased net sales by 2.7 percent in constant dollars to $7.7 billion and increased Adjusted EBITDA by 7.3 percent excluding SARs. In the fourth quarter, we delivered favorable price/mix in every division and in every region. We made significant progress on our 'Get Fit' strategy and, as we move forward, we are well positioned to 'Change the Game.' Our focus will continue to be on improving the quality of our business."
Peribere continued, "The completion of the W. R. Grace & Co. Settlement agreement is a significant development for Sealed Air. It brings closure to this matter after more than a decade, we will no longer incur interest on the settlement liability, and we also anticipate meaningful cash tax benefits over the next several years. This will provide Sealed Air with more financial flexibility and enable us to continue to add value to our business and shareholders alike."
Unless otherwise stated, all results compare 2013 to 2012 and include continuing operations. The rigid medical packaging business ("Medical Rigids"), which the Company sold in December 2013, and Diversey Japan, which the Company sold in November 2012, have been presented as discontinued operations. Reported information is defined as U.S. GAAP. Year-over-year net sales discussions present both reported and constant dollar performance. Constant dollar sales performance excludes the impact of currency translation. Additionally, non-U.S. GAAP adjusted financial measures, such as Adjusted Earnings Before Interest, Taxes and Depreciation and Amortization ("Adjusted EBITDA"), Adjusted Diluted Earnings Per Share ("Adjusted EPS") and Core Tax Rate exclude the impact of special items, such as restructuring charges and other one-time items. Additional detail on cash-settled stock appreciation rights ("SARs") granted as part of the Diversey acquisition is provided in the supplementary information.
Business and Financial Highlights
-In the fourth quarter 2013, the Food Care division increased sales by 4.2 percent in constant dollars primarily due to favorable price/mix of 3.2 percent and continued strength in Latin America and Asia, Middle East, Africa and Turkey ("AMAT"). In the full year 2013, the Food Care division had strong performance, delivering 3.3 percent sales growth in constant dollars and increasing Adjusted EBITDA, excluding SARs, by 8.1 percent to $578.6 million, or 15.2 percent of net sales. Food Care increased volumes by 1.7 percent and had a favorable price mix of 1.6 percent.
-The Diversey Care division, which is undergoing a multi-year turn around, continues to make significant operational and financial improvements. In the fourth quarter 2013, Adjusted EBITDA, excluding SARs, increased 9.5 percent to $56.5 million, or 10.4 percent of net sales. In the full year 2013, Adjusted EBITDA, excluding SARs, increased 6.4 percent to $223.1 million, or 10.3 percent of net sales. The increase in Adjusted EBITDA in the fourth quarter and full year 2013 was primarily attributable to favorable pricing and realization of cost synergies.
-The Product Care division has been focused on improving the mix of its product portfolio and implementing new initiatives to improve pricing disciplines. This strategy resulted in a favorable price/ mix of 1.7 percent in the fourth quarter 2013 on a 3.1 percent increase in volumes.
-As it relates to the W. R. Grace & Co. matter, Sealed Air will no longer incur interest expense related to the settlement liability, which amounted to $48 million in 2013, and the Company anticipates a cash tax benefit in 2015 of more than $200 million. The Company funded the $930 million liability with cash on hand and committed liquidity. In addition, the Company issued 18 million shares which were previously reserved for the Settlement agreement and such shares continued to be included in the diluted shares outstanding.
Fourth Quarter and Full Year 2013 Summary
Fourth quarter 2013 net sales from continuing operations of $2.0 billion increased 3.0 percent on a reported basis and 4.1 percent in constant dollars. Volume and product price/mix increased by 1.4 percent and 2.7 percent, respectively, in the quarter. For the full year 2013, net sales totaled $7.7 billion, a reported increase of 1.7 percent and 2.7 percent in constant dollars. Volume and product price/mix for the full year increased 1.5 percent and 1.2 percent, respectively. Approximately $90 million of net sales from Medical Rigids were reported in discontinued operations.
In the fourth quarter 2013, the Company delivered 8.0 percent growth in AMAT and 6.7 percent in Latin America and experienced improving trends in Europe with 2.6 percent net sales growth, in constant dollars. North America and Japan, Australia and New Zealand ("JANZ") also contributed to solid growth with increases of 3.6 percent and 2.7 percent, respectively. For the full year 2013, net sales increased 8.8 percent for AMAT, 9.7 percent for Latin America, and 2.1 percent for North America. Net sales in Europe and JANZ were essentially unchanged compared to a year ago. Additionally, 2013 reported net sales from Developing Regions1 increased 5.1 percent, or 8.9 percent in constant dollars, accounting for 25.7 percent of total net sales.
Adjusted EBITDA from continuing operations for the fourth quarter 2013 of $261.8 million, or 13.0 percent of net sales, was comparable to fourth quarter 2012. Excluding the impact of SARs, Adjusted EBITDA was $273.1 million, or 13.6 percent of net sales, compared to $275.1 million, or 14.1 percent of net sales, in 2012. The margin decline in the fourth quarter was primarily attributable to higher selling, general and administrative costs and unfavorable supply chain costs, partially offset by cost synergies, favorable mix and price/cost spread and volume growth. The higher costs were partly attributable to an increase of approximately $17 million in performance compensation recorded in the fourth quarter 2013, as compared to the same period a year ago, in recognition of the strong full year-over-year performance in Adjusted EBITDA, working capital management and other key financial metrics.
Full year 2013 Adjusted EBITDA was $1.03 billion, or 13.5 percent of net sales. This compares to $981.3 million, or 13.0 percent of net sales in 2012. Excluding the impact of SARs, Adjusted EBITDA was $1.07 billion, or 13.9 percent of net sales. This represents a 7.3 percent increase compared to Adjusted EBITDA of $1.0 billion in 2012, or 13.2 percent of net sales. This increase was primarily due to higher sales and realization of cost synergies. Incremental cost synergies under the 2011-2014 Integration and Optimization Program were approximately $110 million in 2013 and primarily resulted from headcount reductions, elimination of redundant costs, plant consolidations and procurement and logistics savings. Approximately $15 million of Adjusted EBITDA from Medical Rigids was reported in discontinued operations in each of 2012 and 2013.
On a reported basis, fourth quarter 2013 EPS from continuing operations was $0.02, which included $0.32 per share of special items primarily consisting of a $50 million ($0.23 per share) increase to the Company's income tax provision resulting from an increase in its valuation allowance with respect to the deferred tax asset related to the W. R. Grace & Co. Settlement agreement. This compares to a loss from continuing operations of $1.79 per share in 2012, which included $2.11 of special items, mostly due to the non- cash impairment of goodwill and other intangible assets. Adjusted EPS from continuing operations was $0.34 for the fourth quarter. The Company recognized $0.11 per share in discontinued operations from the sale of Medical Rigids, including a $0.10 per share gain on the sale. This compares to Adjusted EPS of $0.32 in 2012. SARs had an unfavorable impact of $0.05 in the fourth quarters of both 2013 and 2012. The core tax rate was 20.0 percent in the fourth quarter 2013, compared to 21.9 percent in the fourth quarter 2012.
For the full year 2013, reported EPS from continuing operations was $0.44, which included $0.79 per share of special items, mostly due to restructuring charges and the increase in the valuation allowance discussed above. The reported loss of $8.39 per share in 2012 included $9.31 of special items due to the non-cash impairment of goodwill and other intangible assets. Adjusted EPS from continuing operations was $1.23. The Company recognized $0.14 per share in discontinued operations from the sale of Medical Rigids, including $0.10 per share gain on the sale. This compares to $0.91 in 2012. Adjusted EPS from continuing operations for the full year 2013, excluding SARs, was $1.39, as compared to $0.98 in 2012. The core tax rate was 21.8 percent in 2013, compared to 26.1 percent in 2012 and a year-over-year benefit of $0.07 per share.
Cash Flow and Net Debt
As the Company prepared for the W. R. Grace & Co. Settlement agreement, it focused considerable efforts during the last few months of the year on accelerated cash generation, contributing to the net cash provided by operating activities of $624.8 million in 2013. This amount was net of $107.0 million of cash payments for restructuring activities and $46.0 million of cash payments for SARs. In 2012, net cash provided by operating activities was $394.2 million, which was net of $103.4 million of cash payments for restructuring activities and $24.0 million of cash payments for SARs. Capital expenditures were $116.0 million in the full year 2013 as compared to $122.8 million in 2012. Free Cash Flow, defined as cash flow provided by operating activities less capital expenditures, was $508.8 million in 2013, as compared to $271.4 million in 2012. This year-over-year increase primarily reflects higher net earnings and net working capital improvements.
Compared to December 31, 2012, the Company's net debt decreased $446.9 million to $4.3 billion as of December 31, 2013. This decrease was primarily due to cash generated from operating activities and proceeds from the sale of Medical Rigids, partially offset by capital expenditures of $116.0 million and dividend payments of $102.0 million. Net debt included the W. R. Grace & Co. Settlement agreement and related accrued interest of $925.1 million.
Outlook for Full Year 2014
The Company expects net sales to be relatively flat compared to 2013 net sales of $7.7 billion with organic growth offset by product rationalization and an estimated unfavorable impact of more than 2 percent from foreign currency translation. Adjusted EPS, excluding the impact of SARs, is expected to be in the range of $1.50 to $1.60. This represents an estimated increase of 8 percent to 15 percent compared with 2013 Adjusted EPS, excluding SARs, of $1.39. Adjusted EPS guidance excludes the impact of special items. The Company's core tax rate for 2014 is expected to increase to approximately 25 percent.
Adjusted EBITDA for 2014, including non-cash profit sharing expense and excluding the impact of SARs, is estimated to be in the range of $1.050 billion to $1.070 billion. This represents an estimated increase of 1 percent to 3 percent compared with 2013 Adjusted EBITDA of $1.038 billion, including non-cash profit sharing expense and excluding the impact of SARs.
For 2014, the Company anticipates capital expenditures of approximately $170 million and cash restructuring payments of approximately $150 million. As a result of higher capital expenditures and restructuring payments in 2014 as compared to 2013, the Company anticipates 2014 Free Cash Flow to be approximately $410 million.
((Comments on this story may be sent to email@example.com))